Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol Ward

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2005
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupMichel Marty, Francesco Cognetti, Dominique Maraninchi, et al.
Blood|December 20, 2017
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLLNatalie Dimier, Paul Delmar, Carol Ward, et al.
Leukemia & Lymphoma|July 11, 2022
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial designKristine Broglio, Lale Kostakoglu, Carol Ward, et al.
Oncotarget|May 6, 2017
Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cellsJames Meehan, Carol Ward, Arran Turnbull, et al.
Nature Medicine|September 5, 2006
Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosisAdriano G Rossi, Deborah A Sawatzky, Annemieke Walker, et al.
Oncotarget|August 11, 2015
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer modelsCarol Ward, James Meehan, Peter Mullen, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerMartine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, et al.
NPJ Digital Medicine|August 1, 2025
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapiesUlrike Weirauch, Markus Kreuz, Colin Birkenbihl, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|October 28, 2014
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortiumErik O Pettersen, Peter Ebbesen, Roben G Gieling, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2005
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study groupMichel Marty, Francesco Cognetti, Dominique Maraninchi, et al.
Blood|December 20, 2017
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLLNatalie Dimier, Paul Delmar, Carol Ward, et al.
Leukemia & Lymphoma|July 11, 2022
PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial designKristine Broglio, Lale Kostakoglu, Carol Ward, et al.
Oncotarget|May 6, 2017
Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cellsJames Meehan, Carol Ward, Arran Turnbull, et al.
Nature Medicine|September 5, 2006
Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosisAdriano G Rossi, Deborah A Sawatzky, Annemieke Walker, et al.
Oncotarget|August 11, 2015
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer modelsCarol Ward, James Meehan, Peter Mullen, et al.
The New England Journal of Medicine|October 21, 2005
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerMartine J Piccart-Gebhart, Marion Procter, Brian Leyland-Jones, et al.
NPJ Digital Medicine|August 1, 2025
Design specifications for biomedical virtual twins in engineered adoptive cellular immunotherapiesUlrike Weirauch, Markus Kreuz, Colin Birkenbihl, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry|October 28, 2014
Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortiumErik O Pettersen, Peter Ebbesen, Roben G Gieling, et al.
Pageof 5